Table 2 Univariate analyses of biomarkers for progressive disease as best clinical benefit in bmCRPC on Abiraterone-therapy

PSA decline ≥ 50 % no vs. yes

24.9 (3.1–202.1)

No-Bouncing vs. ALP-Bouncing

11.6 (1.4–93.5)

ALP rising after 12 w yes vs. no

6.3 (1.7–22.8)

Visceral Mets. yes vs. no

4.0 (1.2–13.9)

ECOG 2 vs. 0–1

3.3 (1.0–11.1)

LDH normalization no vs. yes

3.0 (0.6–15.6)

LDH BL > UNL yes vs. no

2.2 (0.4–10.9)

ALP BL > UNL yes vs. no

1.3 (0.4–4.3)

AA post-CTX vs. pre-CTX

1.2 (0.4–3.7)

Lnn. Mets. yes vs. no

1.2 (0.4–3.8)

GS ≥ 8 vs. GS < 8

1.2 (0.3–4.4)